Innospec Inc. — Specialty Chemicals. Scored on the same transparent model behind the daily rankings.
★
IOSP
Innospec Inc. · Specialty Chemicals
FCF$110mC
Rev+0.2%C
D/E0.04A-
P/E18.9xB
PEG0.66A-
61Score
$86.59$2.1B
1Y Target$99.33Analyst consensus · 3 analysts
5Y Target$125.41Compound horizon
10Y Target$160.83Long-dated conviction
FCF$110mTTMC
FCF $110m — modest; watch for margin expansion
Rev+0.2%TTM YoYC
Revenue +0.2% — flat, mature phase or headwinds present
D/E0.04A-
D/E 0.04 — less debt than most Basic Materials peers (≈25th pctile)
P/E18.9xB
P/E 18.9 — near the Basic Materials median (≈60th pctile)
PEG0.66A-
PEG 0.66 — strong; Lynch's preferred zone
Forward price target — the 1-year figure is the analyst consensus where the stock is covered; the 5- and 10-year figures compound our earnings estimate from there. The DCF below is a separate cross-check on intrinsic value (what it's worth today), not another target.
Quality-growth score · 61
Quality0.65
Growth0.50
Value0.70
Why this score
Raising its dividend
Durable high returns
Cyclical growth
Entry · Margin of safety
52-week rangeNear 52-week high
6% off the 12-month high
vs DCF fair value24% belowest. fair value ~$114
What the price assumes: free cash flow compounding at ~8% a year for the next decade — vs the ~25% a year our model projects from current growth and analyst estimates.
Quality signals · context only
Gross profitability27% · Bgross profit ÷ total assets (Novy-Marx)
ROIC7.3% · C+return on invested capital — not score-weighted
Why now
Specialty Chemicals · market cap $2.1b. 6% off the 52-week high of $92.14. PEG 0.66 — paying under fair value for the growth rate. 3 sell-side analysts publish a mean 1-yr target of $99.33 (implying +15% upside).
Moat
Moat signals from the quantitative card are modest — profitability and capital efficiency are middle-of-pack. The thesis here depends on softer factors (switching costs, brand, distribution, regulatory protection) not captured by the quality-growth screen.
Risk
Value re-rating depends on a catalyst. Without one — analyst day, divestiture, margin recovery, capital return — the stock can stay cheap on these multiples for years.
Horizon
1-3 yr $99.33 (3-analyst consensus) — multiple re-rating thesis requires a catalyst. 5 yr $125.41 at ~8% CAGR — dividend + buyback compounding. 10 yr $160.83 if the moat survives secular pressure.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
IOSP vs the Top Picks average
Pillar
IOSP
Book avg
Diff
Quality
0.65
0.83
-0.18
Growth
0.50
0.91
-0.41
Value
0.70
0.75
-0.05
Averaged across the 30 names in today's Top Picks (mean score 81.8). A name can beat these averages and still be absent from the book — it also applies concentration limits.
Score history · IOSP
Trend
-2.5 over 33 daily scores
From 63.5 (Jun 22) → 61.0 (now)
One point per daily model run. The range autoscales, so a flat-looking line can still hide 1–2 point moves — read the From → To values for the actual range.
Position sizing · IOSP
$
%
%
Shares to buy
23
Position size
$1,992
4.0% of portfolio
Stop price
$64.94
25% below $86.59
$ at risk if stopped
$497.89
budget $500.00 · 1% of portfolio
Math only — share count is floor(portfolio × risk% ÷ (price × stop%)). Doesn't account for commissions, slippage, gap risk, or position-correlation across your book. Inputs persist locally; never sent to the server. Not investment advice.
Innospec Inc. (IOSP): score, valuation & FAQ
Innospec Inc. (IOSP) is a Specialty Chemicals company that scores 61 out of 100 on the Bull Rankings quality-growth model — a middling reading. The score blends three pillars — quality (durable returns, healthy margins, low leverage), growth (revenue and earnings), and value (valuation versus sector peers) — into one number, refreshed daily; it is a screen, not a buy recommendation.
Its strongest graded signals are D/E (A-) and PEG (A-). On valuation, IOSP sits about 24% below our discounted-cash-flow fair value (a margin of safety) — the current price implies roughly 8% annual free-cash-flow growth over the next decade.
Is IOSP a good stock to buy?
Bull Rankings scores IOSP 61 out of 100 on its quality-growth model, which is a middling reading. That is driven by D/E (A-) and PEG (A-). A score is a quantitative screen of Innospec Inc.'s fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.
Why does IOSP score 61 on Bull Rankings?
The quality-growth score blends three pillars — quality (returns on capital, margins, leverage, earnings quality), growth (revenue and earnings expansion), and value (valuation versus sector peers). IOSP earns its highest marks on D/E (A-) and PEG (A-). Each pillar is graded against sector-aware thresholds, then combined into the single 0–100 score.
Is IOSP overvalued or undervalued?
Based on $86.59, IOSP sits about 24% below our discounted-cash-flow fair value (a margin of safety) — the current price implies roughly 8% annual free-cash-flow growth over the next decade. It trades at a 18.9x× P/E (graded B). Discounted-cash-flow estimates are sensitive to growth and discount-rate assumptions, so treat this as a cross-check, not a price target.
What are the main risks of investing in IOSP?
Value re-rating depends on a catalyst. Without one — analyst day, divestiture, margin recovery, capital return — the stock can stay cheap on these multiples for years.
Bull Rankings is an automated fundamentals screen for research and education. It is not investment advice, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a licensed financial adviser.